These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19857155)

  • 1. Avoiding Guillan-Barré Syndrome following swine origin pandemic H1N1 2009 influenza vaccination.
    Eisen DP; McBryde ES
    J Infect Dis; 2009 Nov; 200(10):1627-8. PubMed ID: 19857155
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jun; 59(21):657-61. PubMed ID: 20520590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic (H1N1) 2009 influenza.
    Polkinghorne B; Ward K; Totaro R
    N S W Public Health Bull; 2010; 21(1-2):41-2. PubMed ID: 21367344
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome.
    Nachamkin I; Shadomy SV; Moran AP; Cox N; Fitzgerald C; Ung H; Corcoran AT; Iskander JK; Schonberger LB; Chen RT
    J Infect Dis; 2008 Jul; 198(2):226-33. PubMed ID: 18522505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré syndrome in children aged <15 years in Latin America and the Caribbean: baseline rates in the context of the influenza A (H1N1) pandemic.
    Landaverde JM; Danovaro-Holliday MC; Trumbo SP; Pacis-Tirso CL; Ruiz-Matus C
    J Infect Dis; 2010 Mar; 201(5):746-50. PubMed ID: 20102270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.
    Yih WK; Lee GM; Lieu TA; Ball R; Kulldorff M; Rett M; Wahl PM; McMahill-Walraven CN; Platt R; Salmon DA
    Am J Epidemiol; 2012 Jun; 175(11):1120-8. PubMed ID: 22582207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pandemic influenza vaccine policy--considering the early evidence.
    Neuzil KM
    N Engl J Med; 2009 Dec; 361(25):e59. PubMed ID: 19745213
    [No Abstract]   [Full Text] [Related]  

  • 8. Guillain-Barré syndrome following H1N1 immunization in a pediatric patient.
    Tremblay ME; Closon A; D'Anjou G; Bussières JF
    Ann Pharmacother; 2010; 44(7-8):1330-3. PubMed ID: 20484170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guillain-Barré syndrome secondary to H1N1 influenza vaccine].
    López Nieto M; Gómez Garrido J; Losa Palacios A; Aguila Manso G
    Rev Clin Esp; 2010 Oct; 210(9):485-6. PubMed ID: 20832792
    [No Abstract]   [Full Text] [Related]  

  • 11. [Guillain-Barre syndrome and the mass vaccination against A/H1N1. No increase of the risk has been reported so far].
    Press R; Andersen O
    Lakartidningen; 2010 Mar 10-16; 107(10):666-7. PubMed ID: 20402249
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of influenza vaccination: Risk-benefit evaluation.
    Wiwanitkit V
    Muscle Nerve; 2010 Aug; 42(2):296; author reply 296. PubMed ID: 20544931
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse effects following pandemic influenza (H1N1) 2009 vaccination.
    Bolam B; Grills N
    Aust N Z J Public Health; 2009 Dec; 33(6):584. PubMed ID: 20078579
    [No Abstract]   [Full Text] [Related]  

  • 14. "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events.
    Evans D; Cauchemez S; Hayden FG
    J Infect Dis; 2009 Aug; 200(3):321-8. PubMed ID: 19563262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition.
    Choe YJ; Cho H; Bae GR; Lee JK
    Vaccine; 2011 Mar; 29(11):2066-70. PubMed ID: 21255684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What we know about influenza vaccine and Guillain-Barré syndrome.
    Enos L
    Oreg Nurse; 2009 Nov; ():5. PubMed ID: 19998739
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.
    Liang XF; Li L; Liu DW; Li KL; Wu WD; Zhu BP; Wang HQ; Luo HM; Cao LS; Zheng JS; Yin DP; Cao L; Wu BB; Bao HH; Xu DS; Yang WZ; Wang Y
    N Engl J Med; 2011 Feb; 364(7):638-47. PubMed ID: 21288090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccine update 2009: questions around the safety of the influenza A (H1N1) vaccine].
    Siegrist CA
    Rev Med Suisse; 2010 Jan; 6(231):67-70. PubMed ID: 20196437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pandemic vaccines and small excess of Guillain-Barre cases.
    BMJ; 2013 Mar; 346():f1714. PubMed ID: 23516147
    [No Abstract]   [Full Text] [Related]  

  • 20. Atypical forms of Guillain-Barré syndrome and H1N1-influenza vaccination.
    Shaikh AG; Termsarasab P; Nwankwo C; Rao-Frisch A; Katirji B
    Vaccine; 2012 May; 30(22):3251-4. PubMed ID: 22429755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.